Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study
Open accessAbstract
BACKGROUND: Statin use could benefit patients with non-alcoholic fatty liver disease (NAFLD), but the evidence is segmented and inconclusive. This multidimensional study comprehensively investigated the potential benefits and mechanism-of-action of statins in NAFLD. METHODS: A cross-sectional investigation was performed within the Rotterdam Study (general population; n = 4.576) and the PERSONS cohort (biopsy-proven NAFLD patients; n = 569). Exclusion criteria were secondary causes for steatosis and insufficient data on alcohol, dyslipidemia or statin use. Associations of statin use with NAFLD (among entire general population), fibrosis and NASH (among NAFLD individuals and patients) were quantified. These results were pooled with available literature in meta-analysis. Last, we assessed statins' anti-lipid and anti-inflammatory effects in 3D cultured human liver organoids and THP-1 macrophages, respectively. FINDINGS: Statin use was inversely associated with NAFLD in the Rotterdam study compared to participants with untreated dyslipidemia. In the PERSONS cohort, statin use was inversely associated with NASH, but not with fibrosis. The meta-analysis included 7 studies and indicated a not significant inverse association for statin use with NAFLD (pooled-Odds Ratio: 0.69, 95% Confidence Interval: 0.46-1.01) and significant inverse associations with NASH (pooled-OR: 0.59, 95% CI: 0.44-0.79) and fibrosis (pooled-OR: 0.48, 95% CI: 0.33-0.70). In vitro, statins significantly reduced lipid droplet accumulation in human liver organoids and downregulated expression of pro-inflammatory cytokines in macrophages. INTERPRETATION: Pooled results demonstrated that statin use was associated with a lower prevalence of NASH and fibrosis and might prevent NAFLD. This may be partially attributed to the anti-lipid and anti-inflammatory characteristics of statins. Given their under-prescription, adequate prescription of statins may limit the disease burden of NAFLD. FUNDING: ZonMw, KWF, NWO, SLO, DGXII, RIDE, National and regional government, Erasmus MC and Erasmus University.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Case-control studies have shown that statin intake is associated with a reduced risk of MASLD, MASH and liver fibrosis, as well as a reduction in the risk of hepatic decompensation, mortality and HCC in individuals with cirrhosis.
“Casecontrol studies have shown that statin intake is associated with a reduced risk of MASLD, MASH and liver fi brosis, 393 as well as a reduction in the risk of hepatic decompensation, mortality and HCC in individuals with cirrhosis.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [393]
The Results and Discussion (pages unavailable) report lower pooled odds of NASH and fibrosis with statin use, but the pooled association with NAFLD was not statistically significant. The Introduction mentions reduced portal pressure in cirrhosis, not reduced hepatic decompensation or mortality; the paper also does not report a reduced HCC risk specifically in people with cirrhosis. Its findings therefore support only part of the attributed claim. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · see citing works
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536 · see citing works
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · see citing works
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · see citing works
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748 · see citing works
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941 · see citing works
Athyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685 · see citing works
Determination of reliability criteria for liver stiffness evaluation by transient elastography
Boursier, J., Zarski, J.-P., de Ledinghen, V., Rousselet, M.-C., Sturm, N., Lebail, B., Fouchard-Hubert, I., Gallois, Y., Oberti, F., Bertrais, S., et al. (2013) · Hepatology · doi:10.1002/hep.25993 · Cited by 662 · see citing works
Lorenzo, C., Williams, K., Hunt, K. J., & Haffner, S. M. (2006) · Diabetes Care · doi:10.2337/dc06-1414 · Cited by 660 · see citing works
Inflammasomes in liver diseases
Szabó, G., & Csák, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.035 · Cited by 498 · see citing works
Abraldeṣ, J. G., Albillos, A., Bañares, R., Turnés, J., González, R., García‐Pagán, J. C., & Bosch, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.043 · Cited by 471 · see citing works
Objectives, design and main findings until 2020 from the Rotterdam Study
Ikram, M. A., Brusselle, G., Ghanbari, M., Goedegebure, A., Ikram, M. K., Kavousi, M., Kieboom, B. C. T., Klaver, C. C. W., de Knegt, R. J., Luik, A. I., et al. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00640-5 · Cited by 450 · see citing works
Statin use and non-alcoholic steatohepatitis in at risk individuals
Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R. M., Pipitone, R., Karja, V., Maggioni, M., Kakela, P., Wiklund, O., Mozzi, E., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.006 · Cited by 390 · see citing works
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.013 · Cited by 272 · see citing works
Chalasani, N. (2005) · Hepatology · doi:10.1002/hep.20671 · Cited by 264 · see citing works
Athyros, V. G., Alexandrides, T. K., Bilianou, H. I., Cholongitas, Ε., Doumas, M. N., Ganotakis, E. S., Goudevenos, J. A., Elisaf, M., Germanidis, G. S., Γιουλεμέ, Ό., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.014 · Cited by 251 · see citing works
Marrone, G., Russo, L., Rosado, E., Hide, D., García‐Cardeña, G., García‐Pagán, J. C., Bosch, J., & Gracia‐Sancho, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.026 · Cited by 244 · see citing works
Yano, M., Matsumura, T., Senokuchi, T., Ishii, N., Murata, Y., Taketa, K., Motoshima, H., Taguchi, T., Sonoda, K., Kukidome, D., et al. (2007) · Circulation Research · doi:10.1161/01.res.0000268411.49545.9c · Cited by 236 · see citing works
Trebicka, J., Hennenberg, M., Odenthal, M., Shir, K., Klein, S., Granzow, M., Vogt, A., Dienes, H., Lammert, F., Reichen, J., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.025 · Cited by 228 · see citing works
Statins and Liver Toxicity: A Meta‐Analysis
de Denus, S., Spinler, S. A., Miller, K., & Peterson, A. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.6.584.34738 · Cited by 218 · see citing works
What is a relevant statin concentration in cell experiments claiming pleiotropic effects?
Björkhem‐Bergman, L., Lindh, J. D., & Bergman, P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03907.x · Cited by 207 · see citing works
Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2
Pignatelli, P., Carnevale, R., Pastori, D., Cangemi, R., Napoleone, L., Bartimoccia, S., Nocella, C., Basili, S., & Violi, F. (2012) · Circulation · doi:10.1161/circulationaha.112.095554 · Cited by 182 · see citing works
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Eslami, L., Merat, S., Malekzadeh, R., Nasseri‐Moghaddam, S., & Aramin, H. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008623.pub2 · Cited by 146 · see citing works
Lee, J. I., Lee, H. W., Lee, K. S., Lee, H. S., & Park, J.-Y. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000845 · Cited by 120 · see citing works
Wang, W., Zhao, C., Zhou, J., Zhen, Z., Wang, Y., & Shen, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076538 · Cited by 117 · see citing works
Nascimbeni, F., Aron‐Wisnewsky, J., Pais, R., Tordjman, J., Poitou, C., Charlotte, F., Bédossa, P., Poynard, T., Clément, K., Ratziu, V., et al. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2015-000075 · Cited by 116 · see citing works
Ciardullo, S., & Perseghin, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154752 · Cited by 111 · see citing works
Ayada, I., van Kleef, L. A., Alferink, L. J. M., Li, P., de Knegt, R. J., & Pan, Q. (2021) · Liver International · doi:10.1111/liv.15139 · Cited by 107 · see citing works
Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia
Blais, P., Lin, M. F., Kramer, J. R., El‐Serag, H. B., & Kanwal, F. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4000-6 · Cited by 93 · see citing works
Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies
Islam, M. M., Poly, T. N., Walther, B. A., Yang, H., & Li, Y. (2020) · Cancers · doi:10.3390/cancers12030671 · Cited by 91 · see citing works
Statins improve NASH via inhibition of RhoA and Ras
Schierwagen, R., Maybüchen, L., Hittatiya, K., Klein, S., Uschner, F. E., Braga, T. T., Franklin, B. S., Nickenig, G., Strassburg, C. P., Plat, J., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00063.2016 · Cited by 83 · see citing works
Cho, Y., Rhee, H., Kim, Y.-E., Lee, M., Lee, B.-W., Kang, E., Cha, B., Choi, J.-Y., & Lee, Y.-H. (2022) · BMC Medicine · doi:10.1186/s12916-022-02288-2 · Cited by 73 · see citing works
Simvastatin maintains function and viability of steatotic rat livers procured for transplantation
Gracia‐Sancho, J., García‐Calderó, H., Hide, D., Marrone, G., Guixé‐Muntet, S., Peralta, C., García‐Pagán, J. C., Abraldeṣ, J. G., & Bosch, J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.005 · Cited by 72 · see citing works
Under-prescription of statins in patients with non-alcoholic fatty liver disease
Ben, M. D., Baratta, F., Polimeni, L., Pastori, D., Loffredo, L., Averna, M. R., Violi, F., & Angelico, F. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.09.011 · Cited by 66 · see citing works
Tabrizi, R., Tamtaji, O. R., Mirhosseini, N. Z., Lankarani, K. B., Akbari, M., Dadgostar, E., Borhani‐Haghighi, A., Peymani, P., Ahmadizar, F., & Asemi, Z. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.010 · Cited by 58 · see citing works
Lombardi, F., Paoletti, L., Carrieri, B., Dell’Aquila, G., Fedecostante, M., Muzio, M. D., Corsonello, A., Lattanzio, F., & Cherubini, A. (2021) · European Geriatric Medicine · doi:10.1007/s41999-021-00471-x · Cited by 50 · see citing works
Pramfalk, C., Parini, P., Gustafsson, U. O., Sahlin, S., & Eriksson, M. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02305.x · Cited by 40 · see citing works
Tang, L., Ma, H., Eslam, M., Wong, G. L., Zhu, P., Chen, S., Leeming, D. J., Karsdal, M. A., Li, G., Huang, O., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154958 · Cited by 40 · see citing works
Thomson, M. J., Serper, M., Khungar, V., Weiss, L. M., Trinh, H., Firpi-Morell, R., Roden, M., Loomba, R., Barritt, A. S., Gazis, D., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.031 · Cited by 38 · see citing works
de Keyser, C. E., Koehler, E. M., Schouten, J. N. L., Visser, L. E., Albert Hofman, D., Janssen, H. L. A., & Stricker, B. H. C. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.04.002 · Cited by 36 · see citing works
Zhou, Y., Gao, F., Liu, W., Wong, G. L., Mahadeva, S., Mustapha, N. R. N., Wang, X., Chan, W., Wong, V. W., & Zheng, M. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16487 · Cited by 34 · see citing works
Wu, X., Zheng, K. I., Boursier, J., Chan, W., Yilmaz, Y. N., Romero‐Gómez, M., El‐Kassas, M., Targher, G., Byrne, C. D., Huang, Z., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101145 · Cited by 34 · see citing works
Wang, L., Li, M., Yu, B., Shi, S., Liu, J., Zhang, R., Ayada, I., Verstegen, M. M. A., van der Laan, L. J. W., Peppelenbosch, M. P., et al. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02176-x · Cited by 30 · see citing works
Abdallah, M., Brown, L., Provenza, J., Tariq, R., Gowda, S. N., & Singal, A. K. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100738 · Cited by 26 · see citing works
Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease
Oni, E., Sinha, P., Karim, A., Martin, S. S., Blaha, M. J., Agatston, A. S., Blumenthal, R. S., Meneghelo, R. S., Conceição, R., Santos, R. D., et al. (2013) · Archives of Medical Research · doi:10.1016/j.arcmed.2013.12.003 · Cited by 19 · see citing works
Diabetes Mellitus, Insulin, Sulfonylurea and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
BoonBee, G. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000410 · Cited by 9 · see citing works
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works
Eslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 186 · see citing works
Mellemkjær, A., Kjær, M. B., Haldrup, D., Grønbæk, H., & Thomsen, K. L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.11.012 · Cited by 109 · see citing works
Zhou, X., Kim, S. U., Yip, T. C., Petta, S., Nakajima, A., Tsochatzis, E. A., Boursier, J., Bugianesi, E., Hagström, H., Chan, W., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-333074 · Cited by 94 · see citing works
Fan, J., Xu, X., Yang, R.-X., Nan, Y., Wei, L., Jia, J., Zhuang, H., Shi, J., Li, X., Cm, S., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00311 · Cited by 85 · see citing works
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 77 · see citing works
MAFLD as part of systemic metabolic dysregulation
Zhao, J., Liu, L., Cao, Y., Gao, X., Targher, G., Byrne, C. D., Sun, D., & Zheng, M. (2024) · Hepatology International · doi:10.1007/s12072-024-10660-y · Cited by 62 · see citing works
Motta, B. M., Masarone, M., Torre, P., & Persico, M. (2023) · Cancers · doi:10.3390/cancers15225458 · Cited by 60 · see citing works
Du, K., Umbaugh, D. S., Wang, L., Jun, J. H., Dutta, R. K., Oh, S., Ren, N., Zhang, Q., Ko, D. C., Ferreira, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57616-w · Cited by 60 · see citing works
Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD
Raza, S., Rajak, S., Yen, P. M., & Sinha, R. A. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00022-5 · Cited by 54 · see citing works
Dua, A., KUMARI, R. R., Singh, M., Kumar, R., Pradeep, S., Ojesina, A. I., & Kumar, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618275 · Cited by 53 · see citing works
Sohn, W., Lee, Y., Kim, S. S., Kim, J. H., Jin, Y., Kim, G., Sung, P. S., Yoo, J., Chang, Y. W., Lee, E. J., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0045 · Cited by 53 · see citing works
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 42 · see citing works
Anti-fibrotic effects of statin drugs: A review of evidence and mechanisms
Dolivo, D., Reed, C. R., Gargiulo, K. A., Rodrigues, A. E., Galiano, R. D., Mustoe, T. A., & Hong, S. J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115644 · Cited by 39 · see citing works
Key takeaways from the updated multidisciplinary European MASLD guidelines
Horn, P., & Tacke, F. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100196 · Cited by 38 · see citing works
Arvanitakis, K., Koufakis, T., Cholongitas, Ε., Francque, S., & Germanidis, G. S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108811 · Cited by 31 · see citing works
Çebi, M., & Yilmaz, Y. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445634 · Cited by 29 · see citing works
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 32 · see citing works
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 27 · see citing works
Statin use and liver-related prognosis among patients with MASLD
Yun, B., Park, H., Lee, J., Kim, B. K., & Yoon, J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101313 · Cited by 23 · see citing works
Allen, A. M., Charlton, M., Cusi, K. J., Harrison, S. A., Kowdley, K. V., Noureddin, M., & Shubrook, J. H. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2325332 · Cited by 22 · see citing works
Role of MASLD in CVD: A review of emerging treatment options
Mollace, R., Longo, S., Nardin, M., Tavernese, A., Musolino, V., Cardamone, A., & Federici, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111891 · Cited by 23 · see citing works
Statins and non-alcoholic fatty liver disease: A concise review
Pereira, E. N. G. D. S., Franco, R. L. C., dos Santos, R. D. C., & Daliry, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117805 · Cited by 21 · see citing works
Zargar, A. H., Bhansali, A. K., Majumder, A., Maheshwari, A., Bhattacharyya, A., Dasgupta, A., Saboo, B., Sethi, B. K., Sanyal, D., Seshadri, K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16496 · Cited by 25 · see citing works
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 20 · see citing works
Protective effects of statins on the incidence of NAFLD –related decompensated cirrhosis in T2DM
Wu, S., Chen, W., Chiang, M., Lo, H., Wu, M., Lee, M., & Soong, R. (2023) · Liver International · doi:10.1111/liv.15656 · Cited by 20 · see citing works
Metabolic-associated fatty liver disease and sarcopenia: A double whammy
Viswanath, A., Fouda, S., Fernandez, C. J., & Pappachan, J. M. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i2.152 · Cited by 20 · see citing works
Lee, J.-H., Kim, J., Kim, J. O., & Kwon, Y.-J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04291-4 · Cited by 13 · see citing works
Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics
Flam, E. L., Haas, J. T., & Staels, B. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119054 · Cited by 16 · see citing works
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14 · see citing works
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease
Yamauchi, Y., Sharpe, L. J., & Brown, A. J. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01168-3 · Cited by 15 · see citing works
Raggi, P., Milić, J., Manicardi, M., Cinque, F., Swain, M. G., Sebastiani, G., & Guaraldi, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117523 · Cited by 14 · see citing works
Katsuyama, H., Hakoshima, M., Kaji, E., Mino, M., Kakazu, E., Iida, S., Adachi, H., Kanto, T., & Yanai, H. (2024) · Biomedicines · doi:10.3390/biomedicines12051001 · Cited by 13 · see citing works
Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD
Iwaszko-Sochal, K., Kasztelan‐Szczerbińska, B., & Cichoż‐Lach, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176148 · Cited by 13 · see citing works
Bernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 16 · see citing works
Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Prasoppokakorn, T. (2025) · Livers · doi:10.3390/livers5010004 · Cited by 11 · see citing works
Santos, H. O., & Penha-Silva, N. (2025) · Nutrition · doi:10.1016/j.nut.2024.112617 · Cited by 11 · see citing works
Targeting THR-β for MASLD Treatment: Current Progression and Emerging Prospects
Li, J., Chen, R., Zhang, J., He, J., Wang, Y., & Li, Y. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03114 · Cited by 11 · see citing works
Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients
Eslami, Z., Aghili, S. S., & Ghafi, A. G. (2024) · Chonnam Medical Journal · doi:10.4068/cmj.2024.60.1.13 · Cited by 10 · see citing works
Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393333 · Cited by 13 · see citing works
Choudhury, A. K., Rajaram, R. B., & Sarin, S. K. (2024) · Hepatology International · doi:10.1007/s12072-024-10711-4 · Cited by 9 · see citing works
Liu, J., Yang, F., Gao, B., Yang, L., Cao, Y., & Zhou, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01574-w · Cited by 9 · see citing works
Association between the NHHR and hepatic steatosis and liver fibrosis: a population-based study
Yang, X., Yan, H., Guo, R., & Chen, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-90818-2 · Cited by 8 · see citing works
Le, P., Tatar, M., Rothberg, M. B., Wilson, L., Allende, D. S., Diehl, A. M., Loomba, R. S., Chalasani, N., Neuschwander‐Tetri, B. A., Kowdley, K. V., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003455 · Cited by 8 · see citing works
Sun, T., Lv, H., Shao, H., Zhang, X., Wang, A., Zhang, W., Liu, F., & Ling, P. (2025) · Marine Drugs · doi:10.3390/md23060228 · Cited by 8 · see citing works
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 8 · see citing works
Bradshaw, D., Abramowicz, I., Bremner, S. A., Verma, S., Gilleece, Y. C., Kirk, S., Nelson, M. R., Housman, R., Miras, H., Orkin, C. M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288598 · Cited by 8 · see citing works
Management of Cardiovascular Risk in the Non‑alcoholic Fatty Liver Disease Setting
Luque-Linero, P., & Castilla‐Guerra, L. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.19 · Cited by 10 · see citing works
Wang, S., Lu, K., Lin, L., Li, G., Han, Y., Lin, Z., Chu, Q., Wu, K., Liu, P., Zhou, G., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314961 · Cited by 7 · see citing works
Role of cholesterol homeostasis in MASH-driven hepatocellular carcinoma: not just a neutral fat
Ribas, V. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00048 · Cited by 8 · see citing works
Yoo, J., Jeon, J., Baik, M., & Kim, J. (2024) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-024-00205-9 · Cited by 6 · see citing works
Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease
Osman, A., Shavva, V. S., Tarnawski, L., Dai, W., Borg, F., Olofsson, V. V., Liu, T., Saliba‐Gustafsson, P., Simini, C., Pedrelli, M., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20032 · Cited by 6 · see citing works
Resmetirom directly inhibits lipid accumulation in human liver-derived organoids
Li, J., Ayada, I., & Pan, Q. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.022 · Cited by 6 · see citing works
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 7 · see citing works
Statins in Chronic Liver Disease: Review of the Literature and Future Role
Pham, N., & Benhammou, J. N. (2024) · Seminars in Liver Disease · doi:10.1055/a-2319-0694 · Cited by 5 · see citing works
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 6 · see citing works
Zambuzzi, W. F., Ferreira, M. R., Wang, Z.-F., & Peppelenbosch, M. (2025) · Biology · doi:10.3390/biology14060669 · Cited by 6 · see citing works
Feng, B., Li, F., Lan, Y., Wang, X., Chen, S., Yang, C., Yin, M., Cui, F., Wang, G., Zhou, D., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae546 · Cited by 4 · see citing works
Williams, D. M., Ali, J., Cragg, J., Ch’ng, C. L., Williams, N. W., Stephens, J. W., & Min, T. (2024) · Cureus · doi:10.7759/cureus.75993 · Cited by 4 · see citing works
Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases
Commins, I., Clayton‐Chubb, D., Janko, N., Majeed, A., Kemp, W. W., & Roberts, S. K. (2026) · Medical Sciences · doi:10.3390/medsci14010084 · Cited by 4 · see citing works
Brouwer, W. P., Vonghia, L., Thiele, M. S., Schattenberg, J. M., Anastasiou, F., Beckmann, S., Bugianesi, E., Castéra, L., Caussy, C., Cordie, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101798 · Cited by 6 · see citing works
Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
van Kleef, L. A., Michel, M. S., Alkhouri, N., Brouwer, W. P., & Schattenberg, J. M. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s559331 · Cited by 4 · see citing works
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6 · see citing works
Impact of statins in the liver: A bane or a boon?
Zacharia, G. S., Jacob, A., Karichery, M., & Sasidharan, A. (2024) · Canadian Liver Journal · doi:10.3138/canlivj-2023-0028 · Cited by 4 · see citing works
Theel, W. B., de Jong, V., Cabezas, M. C., Grobbee, D. E., Jukema, J. W., & Trompet, S. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14368 · Cited by 5 · see citing works
de Jong, V., Theel, W. B., Cabezas, M. C., Grobbee, D. E., Jukema, J. W., & Trompet, S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101337 · Cited by 4 · see citing works
Hu, W., Chen, Y., Tan, W., Wang, Y., Huang, D., & Yuan, H. (2025) · Natural Product Communications · doi:10.1177/1934578x241302020 · Cited by 4 · see citing works
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 4 · see citing works
Cav3.2 deletion attenuates nonalcoholic fatty liver disease in mice
Li, X., Hu, C., Luo, S., Dai, F., Li, C., Zhou, W., Wang, J., Chen, H., Wang, Z., Long, T., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148812 · Cited by 4 · see citing works
Drzewicka, K., Głuchowska, K. M., Mlącki, M., Hofman, B., Tuszyńska, I., Ryan, T. A. J., Piwowar, K., Wilczyński, B., Dymkowska, D., Grzybowski, M. M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544973 · Cited by 3 · see citing works
Kim, S. G., Kang, J. H., Park, S. J., Yu, J., Jeong, S., Park, S., Ko, A., & Park, S. M. (2026) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-25-0287 · Cited by 3 · see citing works
Polpichai, N., Saowapa, S., Jaroenlapnopparat, A., Sierra, L., Danpanichkul, P., Fangsaard, P., Wattanachayakul, P., & Kaewdech, A. (2024) · Livers · doi:10.3390/livers4040046 · Cited by 3 · see citing works
Jamialahmadi, T., Reiner, Ž., Riahi, M. M., Emami, S. A., Tayarani‐Najaran, Z., Salehabadi, S., Kesharwani, P., Al‐Rasadi, K., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230918114451 · Cited by 3 · see citing works
Interaction of high lipogenic states with titanium on osteogenesis
Pinto, T. S., van der Eerden, B. C. J., Schreuders‐Koedam, M., van de Peppel, J., Ayada, I., Pan, Q., Verstegen, M. M. A., van der Laan, L. J. W., Fuhler, G. M., Zambuzzi, W. F., et al. (2024) · Bone · doi:10.1016/j.bone.2024.117242 · Cited by 3 · see citing works
Wu, W., Wu, D., Cao, C., Zhou, R., Ding, S.-H., Ying, Y., Sun, D., & Hu, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618576 · Cited by 4 · see citing works
Qin, Y., Chhetri, P. D., Theusch, E., Lim, G., Teker, S. S., Kuang, Y.-L., Raftar, S. K. A., Mehraban, M. H., Munoz-Howell, A., Saxena, V., et al. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf066 · Cited by 2 · see citing works
Alhawiti, N. M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1728096 · Cited by 3 · see citing works
Cattazzo, F., Cinque, F., di Maria, V., Vicardi, M., Mantovani, A., Zoncapè, M., Natola, L. A., Sacerdoti, D., Lombardi, R., & Dalbeni, A. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.05.010 · Cited by 2 · see citing works
Jarvis, H., Brennan, P., Casanovas, T., Casler, K., Desai, M., Evans, P. H., Dillon, J. F., Grattagliano, I., Hallsworth, K., Hebditch, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00015-4 · Cited by 3 · see citing works
Shen, H., Wang, C.-H., Yang, C.-W., Lin, Y., Yeh, H., Perng, D., Yang, Y.-Y., & Hou, M. (2024) · Medicine · doi:10.1097/md.0000000000038530 · Cited by 2 · see citing works
Reducing complications of metabolic dysfunction–associated steatotic liver disease
Wada, N., Iwaki, M., Kobayashi, T., Nakajima, A., & Yoneda, M. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2502549 · Cited by 1 · see citing works
Wang, J., Ding, D., Shao, X., Ma, L., Xu, J., Melehani, J. H., Boyette, L. B., Watkins, T. R., Jia, C., Malkov, V. A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16443 · Cited by 1 · see citing works
Diagnose und Therapie der MASLD
Horn, P., & Tacke, F. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01896-3 · Cited by 1 · see citing works
Demidova, T. Y., Расуловна, Б. А., & Омариевна, У. Ф. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-2-09 · Cited by 1 · see citing works
Cardoso, C. R. L., Villela‐Nogueira, C. A., Salles, G. F., & Leite, N. C. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104478 · Cited by 1 · see citing works
Metabolic Liver Disease Beyond the Liver
Gastaldelli, A., Tacke, F., & Holleboom, A. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.003 · Cited by 1 · see citing works
Jiménez-González, C., Iruzubieta, P., Alonso‐Peña, M., Cayon, L., & Crespo, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1884657 · Cited by 1 · see citing works
Autophagy in MASLD : A Metabolic and Precision Medicine Perspective
Cazzaniga, A., Frigo, S., Cherubini, A., Rrapaj, E., & Valenti, L. V. C. (2026) · Liver International · doi:10.1111/liv.70816 · Cited by 1 · see citing works
Lau, K. C.-H., Wong, V. W., Kong, A. P. S., Wong, G. L., Lai, J. C., Chu, C. W., & Yip, T. C. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70656 · Cited by 1 · see citing works
Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy
Averna, M., Hussain, M. M., & Norata, G. D. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01336-1 · Cited by 1 · see citing works
Praxisorientierte Strategien für Screening, Diagnostik und Therapie der NAFLD
Kreimeyer, H., Manka, P. P., & Canbay, A. E. (2023) · Gastro-News · doi:10.1007/s15036-023-3265-4 · Cited by 1 · see citing works
Role of liver sinusoidal endothelial cells in the diagnosis and treatment of liver diseases
Fernández‐Iglesias, A., & Gracia‐Sancho, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00023-1 · Cited by 1 · see citing works
Zhang, Y., & Xu, C. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.1211015 · Cited by 1 · see citing works
Medications for Weight Loss and MASLD
Im, G. Y., Asgharpour, A., Aby, E. S., Stine, J. G., Mellinger, J. L., Luther, J., Izzy, M. J., Haque, L., Lee, B. T., Cotter, T. G., et al. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002147 · Cited by 1 · see citing works
Drzewicka, K., Głuchowska, K., Mlącki, M., Hofman, B., Tuszyńska, I., Ryan, T., Piwowar, K., Wilczyński, B., Dymkowska, D., Dymek, B., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4905908
Metabolische Dysfunktion-assoziierte steatotische Lebererkrankung (MASLD)
Manka, P. P., Kreimeyer, H., & Canbay, A. E. (2024) · Gastroenterologie up2date · doi:10.1055/a-2123-0462
Drzewicka, K., Głuchowska, K., Mlącki, M., Hofman, B., Tuszyńska, I., Ryan, T., Piwowar, K., Wilczyński, B., Dymkowska, D., Dymek, B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.27.620490
Zheng, A., Song, S., Xu, Q., & Liu, T. (2025) · Natural Product Communications · doi:10.1177/1934578x241306938
Cholesterol-Responsive Interaction of NFE2L1-INSIG1 Controls VLDL Secretion and MASH PathogenesisPreprint
Deng, S., Freed, J., Lee, G. Y., Askin, G., Cao, Z., Cakici, Ö., Yuan, B., Hui, S. T., Inouye, K., Graupera, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.09.657856
- Authors
- Ayada, I., van Kleef, L. A., Zhang, H., Liu, K., Li, P., Abozaid, Y. J., Lavrijsen, M., Janssen, H. L. A., van der Laan, L. J. W., Ghanbari, M., Peppelenbosch, M. P., Zheng, M.-H., de Knegt, R. J., & Pan, Q.
- Affiliations
- Erasmus MC (NL)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- University of Toronto (CA)
- Wenzhou Medical University (CN)
- Corresponding author
- Zheng, Ming-Hua
- Pan, Qiuwei
- ORCID
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 87
- Pages
- 104392
- ISSN
- 2352-3964 (ISSN-L)
- PMC
- PMC9758527
- OpenAlex
- W4310847620
- Cited by
- 117
- References
- 48
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 43 · 2023: 8
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- EBioMedicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerie van Onderwijs, Cultuur en Wetenschap
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (91719300, 10140)
- ZonMw
- European Commission
- Ministerie van Volksgezondheid, Welzijn en Sport
- KWF Kankerbestrijding
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liver fibrosis, dyslipidemia, anti-inflammatory activity, lipid droplet accumulation, liver organoids, macrophages, inflammatory cytokines, statin prescribing
- MeSH terms
- Cross-Sectional Studies, Fibrosis, Humans, Liver, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
